PMID- 27730400
OWN - NLM
STAT- MEDLINE
DCOM- 20171211
LR  - 20240213
IS  - 1873-4626 (Electronic)
IS  - 1091-255X (Linking)
VI  - 20
IP  - 12
DP  - 2016 Dec
TI  - Expression of VEGF-D, SMAD4, and SMAD7 and Their Relationship with 
      Lymphangiogenesis and Prognosis in Colon Cancer.
PG  - 2074-2082
AB  - AIM: The vascular endothelial growth factor (VEGF) and TGF-beta1 pathways play 
      important roles in cancer. However, few studies have evaluated the expression and 
      roles of VEGF-D, SMAD4, and SMAD7 in colon cancer, and the conclusions remain 
      controversial. To clarify the roles of VEGF-D, SMAD4, and SMAD7 in colon cancer, 
      we examined their expression and evaluated correlations with lymphangiogenesis, 
      prognosis, and chemotherapeutic outcome. METHODS: The expression of VEGF-D, 
      SMAD4, and SMAD7 was immunohistochemically examined in 251 primary colon cancer 
      samples obtained from the Harbin Medical University. RESULTS: The expression of 
      VEGF-D, SMAD4, and SMAD7 was identified in 71.7, 41.0, and 69.7 % of samples, 
      respectively. Positive expression of VEGF-D and SMAD7 and lost expression of 
      SMAD4 were significantly correlated with lymph node metastasis and high lymphatic 
      vessel density. VEGF-D and SMAD7 were found to be independent indicators of 
      prognosis and chemotherapy outcome, and positive expression of either VEGF-D or 
      SMAD7 was associated with significantly shorter overall survival and disease-free 
      survival (OS and DFS) than negative expression in all 251 patients (P < 0.001 for 
      OS and DFS) and patients following chemotherapy (P < 0.001 for OS and DFS). 
      CONCLUSION: VEGF-D, SMAD4, and SMAD7 were involved in lymphangiogenesis and lymph 
      node metastasis. VEGF-D and SMAD7 can serve as predictors of prognosis and 
      chemotherapeutic outcome in colon cancer.
FAU - Su, Fei
AU  - Su F
AD  - College of Bioinformatics Science and Technology, Harbin Medical University, 
      Harbin, 150081, People's Republic of China.
FAU - Li, Xuemei
AU  - Li X
AD  - Department of Anatomy, Harbin Medical University, 57 Baojian Road, Harbin, 
      150081, People's Republic of China.
FAU - You, Kai
AU  - You K
AD  - Department of Anatomy, Harbin Medical University, 57 Baojian Road, Harbin, 
      150081, People's Republic of China.
FAU - Chen, Mingwei
AU  - Chen M
AD  - Department of Anatomy, Harbin Medical University, 57 Baojian Road, Harbin, 
      150081, People's Republic of China.
FAU - Xiao, Jianbing
AU  - Xiao J
AD  - Department of Anatomy, Harbin Medical University, 57 Baojian Road, Harbin, 
      150081, People's Republic of China.
FAU - Zhang, Yafang
AU  - Zhang Y
AD  - Department of Anatomy, Harbin Medical University, 57 Baojian Road, Harbin, 
      150081, People's Republic of China.
FAU - Ma, Jing
AU  - Ma J
AD  - Department of Anatomy, Harbin Medical University, 57 Baojian Road, Harbin, 
      150081, People's Republic of China.
FAU - Liu, Baoquan
AU  - Liu B
AD  - Department of Anatomy, Harbin Medical University, 57 Baojian Road, Harbin, 
      150081, People's Republic of China. lbquan505@163.com.
LA  - eng
PT  - Journal Article
DEP - 20161011
PL  - Netherlands
TA  - J Gastrointest Surg
JT  - Journal of gastrointestinal surgery : official journal of the Society for Surgery 
      of the Alimentary Tract
JID - 9706084
RN  - 0 (Antineoplastic Agents)
RN  - 0 (SMAD4 protein, human)
RN  - 0 (SMAD7 protein, human)
RN  - 0 (Smad4 Protein)
RN  - 0 (Smad7 Protein)
RN  - 0 (VEGFD protein, human)
RN  - 0 (Vascular Endothelial Growth Factor D)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/therapeutic use
MH  - Colonic Neoplasms/drug therapy/*metabolism/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - *Lymphangiogenesis
MH  - Lymphatic Metastasis
MH  - Lymphatic Vessels/pathology
MH  - Male
MH  - Middle Aged
MH  - Smad4 Protein/*metabolism
MH  - Smad7 Protein/*metabolism
MH  - Survival Rate
MH  - Vascular Endothelial Growth Factor D/*metabolism
MH  - Young Adult
OTO - NOTNLM
OT  - Colon cancer
OT  - Prognosis
OT  - SMAD4
OT  - SMAD7
OT  - VEGF-D
EDAT- 2016/10/13 06:00
MHDA- 2017/12/12 06:00
CRDT- 2016/10/13 06:00
PHST- 2016/05/12 00:00 [received]
PHST- 2016/09/29 00:00 [accepted]
PHST- 2016/10/13 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2016/10/13 06:00 [entrez]
AID - S1091-255X(23)06774-4 [pii]
AID - 10.1007/s11605-016-3294-9 [doi]
PST - ppublish
SO  - J Gastrointest Surg. 2016 Dec;20(12):2074-2082. doi: 10.1007/s11605-016-3294-9. 
      Epub 2016 Oct 11.